HE3286 Reduces Axonal Loss and Preserves Retinal Ganglion Cell Function in Experimental Optic Neuritis
Open accessThe DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
PURPOSE: Optic nerve inflammation, demyelination, and axonal loss are all prominent features of optic neuritis. While corticosteroids hasten visual recovery in optic neuritis, no treatment improves final visual outcomes. HE3286 (17α-ethynyl-5-androstene-3β,7β,17β-triol), a synthetic derivative of a natural steroid, β-AET (5-androstene-3β,7β,17β-triol), exerts anti-inflammatory effects in several disease models and has purported neuroprotective effects as well. HE3286's ability to suppress optic neuritis was examined in experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis. METHODS: Experimental autoimmune encephalomyelitis was induced in C57/BL6 mice. Mice were treated daily with intraperitoneal vehicle or 40 mg/kg HE3286. Visual function was assessed by optokinetic responses (OKR) at baseline and every 10 days until euthanasia at 40 days post immunization. Retinas and optic nerves were isolated. Inflammation (hematoxylin and eosin and Iba1 staining), demyelination (Luxol fast blue staining), and axonal loss (neurofilament staining) were assessed in optic nerve sections. Retinal ganglion cells (RGCs) were immunolabeled with Brn3a antibodies to quantify RGC survival. RESULTS: Progressive decreases in OKR occurred in vehicle-treated EAE mice, and HE3286 treatment reduced the level of this vision loss. HE3286 also attenuated the degree of inflammation, demyelination, and axonal loss in EAE optic nerves as compared to nerves from vehicle-treated EAE mice. Retinal ganglion cell loss that occurred in both vehicle- and HE3286-treated EAE mice was reduced in the temporal retinal quadrant of HE3286-treated mice. CONCLUSIONS: HE3286 suppresses inflammation, reduces demyelination and axonal loss, and promotes RGC survival during experimental optic neuritis. Importantly, HE3286 treatment also preserves some RGC function. Results suggest that HE3286 is a potential novel treatment for optic neuritis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
Paty, D. W., Li, D. K. B., the UBC MS/MRI Study Group, & the IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.662 · Cited by 1,967
Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Rose, J. W., Schiffer, R. B., et al. (1995) · Neurology · doi:10.1212/wnl.45.7.1268 · Cited by 1,898
Parallel processing in the mammalian retina
Wässle, H. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1497 · Cited by 1,252
The fundamental plan of the retina
Masland, R. H. (2001) · Nature Neuroscience · doi:10.1038/nn0901-877 · Cited by 1,237
Hartung, H.-P., Gonsette, R., Konig, N., Kwiecinski, H., Guseo, A., Morrissey, S. P., Krapf, H., & Zwingers, T. (2002) · The Lancet · doi:10.1016/s0140-6736(02)12023-x · Cited by 946
Rapid Quantification of Adult and Developing Mouse Spatial Vision Using a Virtual Optomotor System
Prusky, G. T., Alam, N. M., Beekman, S., & Douglas, R. M. (2004) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.04-0541 · Cited by 772
Rodieck, R. W. (1998) · Optometry and Vision Science · doi:10.1097/00006324-199812000-00004 · Cited by 659
(1998) · Cited by 601
Kroboth, P. D., Salek, F. S., Pittenger, A. L., Fabian, T. J., & Frye, R. F. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922007903 · Cited by 518
(2004) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(03)00862-6 · Cited by 236
Oral Resveratrol Reduces Neuronal Damage in a Model of Multiple Sclerosis
Shindler, K. S., Ventura, E., Dutt, M., Elliott, P., Fitzgerald, D. C., & Rostami, A. (2010) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0b013e3181f7f833 · Cited by 203
Self-citationEvolving Management of Optic Neuritis and Multiple Sclerosis
Arnold, A. C. (2005) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2005.01.031 · Cited by 175
SIRT1 Activation Confers Neuroprotection in Experimental Optic Neuritis
Shindler, K. S., Ventura, E., Rex, T. S., Elliott, P., & Rostami, A. (2007) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-0131 · Cited by 171
Self-citationResveratrol Neuroprotection in a Chronic Mouse Model of Multiple Sclerosis
Fonseca-Kelly, Z., Nassrallah, M., Uribe, J., Khan, R. S., Dine, K., Dutt, M., & Shindler, K. S. (2012) · Frontiers in Neurology · doi:10.3389/fneur.2012.00084 · Cited by 166
Self-citationYonehara, K., Ishikane, H., Sakuta, H., Shintani, T., Nakamura-Yonehara, K., Kamiji, N. L., Usui, S., & Noda, M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004320 · Cited by 162
Shindler, K. S., Ventura, E. S., Dutt, M., & Rostami, A. M. (2008) · Experimental Eye Research · doi:10.1016/j.exer.2008.05.017 · Cited by 153
Self-citationThe Actions of Exogenous Dehydroepiandrosterone in Experimental Animals and Humans
Svec, F., & Porter, J. R. (1998) · Experimental Biology and Medicine · doi:10.3181/00379727-218-44285 · Cited by 151
Dillon, J. (2005) · Current Drug Target -Inflammation & Allergy · doi:10.2174/1568010054022079 · Cited by 115
Shindler, K. S., Guan, Y., Ventura, E. S., Bennett, J., & Rostami, A. M. (2006) · Multiple Sclerosis Journal · doi:10.1177/1352458506070629 · Cited by 107
Self-citationSIRT1 activating compounds reduce oxidative stress and prevent cell death in neuronal cells
Khan, R. S., Fonseca-Kelly, Z., Callinan, C., Zuo, L., Sachdeva, M. M., & Shindler, K. S. (2012) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2012.00063 · Cited by 105
Self-citationOptic Neuritis and Retinal Ganglion Cell Loss in a Chronic Murine Model of Multiple Sclerosis
Quinn, T. A., Dutt, M., & Shindler, K. S. (2011) · Frontiers in Neurology · doi:10.3389/fneur.2011.00050 · Cited by 101
Self-citationKim, S.-W., Lim, C., Kim, J., Shin, J., Lee, S., Lee, M., & Lee, J.-K. (2010) · Neurotoxicity Research · doi:10.1007/s12640-010-9231-x · Cited by 98
SIRT1 Promotes RGC Survival and Delays Loss of Function Following Optic Nerve Crush
Zuo, L., Khan, R. S., Lee, V., Dine, K., Wu, W., & Shindler, K. S. (2013) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-12157 · Cited by 80
Self-citationKhan, R. S., Dine, K. E., Sarma, J. D., & Shindler, K. S. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-3 · Cited by 78
Self-citationTeuscher, C., Bunn, J. Y., Fillmore, P. D., Butterfield, R. J., Zachary, J. F., & Blankenhorn, E. P. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63416-5 · Cited by 65
Lu, M., Patsouris, D., Li, P., Flores-Riveros, J., Frincke, J. M., Watkins, S., Schenk, S., & Olefsky, J. M. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00668.2009 · Cited by 43
Auci, D. L., Reading, C. L., & Frincke, J. M. (2008) · Autoimmunity Reviews · doi:10.1016/j.autrev.2008.11.011 · Cited by 40
AUCI, D., KALER, L., SUBRAMANIAN, S., HUANG, Y., FRINCKE, J., READING, C., & OFFNER, H. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1423.066 · Cited by 39
Contributions of retinal direction‐selective ganglion cells to optokinetic responses in mice
Sugita, Y., Miura, K., Araki, F., Furukawa, T., & Kawano, K. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12284 · Cited by 32
Wang, T., Villegas, S., Huang, Y., White, S. K., Ahlem, C. N., Lu, M. M., Olefsky, J. M., Reading, C. L., Frincke, J. M., Alleva, D. G., et al. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.161182 · Cited by 28
Self-citationOffner, H., Firestein, G. S., Boyle, D. L., Pieters, R. H. H., Frincke, J. M., Garsd, A., White, S. K., Reading, C. L., & Auci, D. L. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.145086 · Cited by 26
Reading, C. L., Frincke, J. M., & White, S. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032147 · Cited by 21
HE3286: A Novel Synthetic Steroid as an Oral Treatment for Autoimmune Disease
Ahlem, C. N., Auci, D. L., Mangano, K., Reading, C. L., Frincke, J. M., Stickney, D. R., & Nicoletti, F. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04798.x · Cited by 18
Self-citationOral treatment with HE3286 ameliorates disease in rodent models of rheumatoid arthritis
Nicoletti, F. (2010) · International Journal of Molecular Medicine · doi:10.3892/ijmm_00000385 · Cited by 16
Nicoletti, F., Philippens, I. H. C. H. M., Fagone, P., Ahlem, C. N., Reading, C. L., Frincke, J. M., & Auci, D. L. (2012) · Parkinson s Disease · doi:10.1155/2012/969418 · Cited by 15
Self-citationAhlem, C. N., Kennedy, M. R., Page, T. M., Reading, C. L., White, S. K., McKenzie, J. J., Cole, P. I., Stickney, D. R., & Frincke, J. M. (2011) · PubMed · Cited by 14
Self-citationPaty, D. W., Li, D. K. B., & the UBC MS/MRI Study Group, A. T. I. M. S. S. G. (2011) · Neurology · doi:10.1212/01.wnl.0000407006.93844.fb · Cited by 13
HE3286, an oral synthetic steroid, treats lung inflammation in mice without immune suppression
Conrad, D., Wang, A., Pieters, R. H. H., Nicoletti, F., Mangano, K., van Heeckeren, A. M., White, S. K., Frincke, J. M., Reading, C. L., Stickney, D. R., et al. (2010) · Journal of Inflammation · doi:10.1186/1476-9255-7-52 · Cited by 12
Role of myelin antigens in murine relapsing experimental allergic encephalomyelitis.
Fd, L. (1984) · PubMed · Cited by 12
Cited by
Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies
Buccellato, F. R., D’Anca, M., Tartaglia, G. M., Del Fabbro, M., Scarpini, E., & Galimberti, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813900 · Cited by 94
Reading, C. L., Ahlem, C. N., & Murphy, M. F. (2021) · Neurodegenerative Disease Management · doi:10.2217/nmt-2021-0022 · Cited by 84
Self-citationRetinal Cell Degeneration in Animal Models
Niwa, M., Aoki, H., Hirata, A., Tomita, H., Green, P. G., & Hara, A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17010110 · Cited by 62
Novel Therapeutics in Glaucoma Management
Bucolo, C., Platania, C. B. M., Drago, F., Bonfiglio, V. M. E., Reibaldi, M., Avitabile, T., & Uva, M. G. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666170915142727 · Cited by 54
Boghozian, R., McKenzie, B. A., Saito, L. B., Mehta, N., Branton, W. G., Lu, J., Baker, G. B., Noorbakhsh, F., & Power, C. (2017) · Glia · doi:10.1002/glia.23179 · Cited by 45
Metadata
- Authors
- Khan, R. S., Dine, K., Luna, E., Ahlem, C., & Shindler, K. S.
- Affiliations
- University of Pennsylvania (US)
- Harbor Therapeutics, Inc., San Diego, California, United States
- Corresponding author
- Shindler, Kenneth S.
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2014-09-11
- Volume
- 55
- Issue
- 9
- Pages
- 5744
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- PMC
- PMC4161484
- OpenAlex
- W2012637873
- Cited by
- 33
- References
- 41
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 2 · 2023: 4 · 2022: 2 · 2021: 2 · 2020: 4 · 2019: 4 · 2018: 3 · 2017: 5 · 2016: 2 · 2015: 1
- FWCI
- 1.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- public-domain
- Locations
- Investigative Ophthalmology & Visual Science (publishedVersion, public-domain)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- F. M. Kirby Foundation
- Research to Prevent Blindness
- James N. Kirby Foundation
- National Institutes of Health
- National Eye Institute (R01EY019014, EY019014, P30EY001583)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- optic neuritis, experimental autoimmune encephalomyelitis, retinal ganglion cell survival, axonal loss, demyelination, neuroprotection, anti-inflammatory steroids, multiple sclerosis model, visual function
- MeSH terms
- Animals, Anti-Inflammatory Agents, Axons, Dehydroepiandrosterone, Disease Models, Animal, Encephalomyelitis, Autoimmune, Experimental, Female, Mice, Inbred C57BL, Optic Neuritis, Retinal Ganglion Cells, Neuroprotective Agents, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.